Partnership insights
Collaborating, innovating, and finding new ways together to improve outcomes
Much more can be achieved when all players in the life sciences and pharmaceutical industries work together, in a truly collaborative way. At ICON, this means working in a way that goes beyond a traditional CRO. It means being a trusted partner.
Exploring partnership culture and its impact on outsourcing and operational strategy
Partnership culture within the clinical research industry has often been overlooked as a component of a successful outsourcing strategy. However, culture can support, inform, and maintain strategies and operational decision-making.
Webinar: Exploring partnership culture and its impact on outsourcing and operational strategy
In this webinar, Sanofi and ICON discuss how they created a shared partnership/alliance culture, which has evolved both the outsourcing strategy and operating model. Attendees will learn about the specific tools and methods used to develop and support the Sanofi / ICON partnership, including:
- Adaptation of the 9 Box Grid to assess cultural alignment and outsourcing and operational strategy, identifying areas of strength and opportunities for development
- An “ABCs of Culture” framework, designed to build cross-organisational cultural alignment.
The evolving relationship between sponsors and CROs
In this Q&A and accompanying podcast, Jeff James provides his perspectives on how CROs have matured to become true partners that offer expansive clinical trial and drug development services, and he spotlights ICON’s approach towards collaboration.
Sponsor and CRO pharmacovigilance and safety alliances
This whitepaper outlines the best practices and model options for ensuring success when outsourcing pharmacovigilance and patient safety services.
Rare disease registries: practical ways to build trust and collaboration with patient advocacy groups
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
Engaging physicians to support and increase clinical research activity
More and more healthcare institutions are looking to increase their research portfolio however engagement of busy physicians is always a challenge.
Partnership blogs and media contributions
-
Media article: Partnership set to make therapies ‘reach patients sooner’
ICON's partnership with Advarra will integrate ICON’s global clinical trial solutions and services with Advarra’s site CTMSs, eISF, and eSource systems, which are already used by more than 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres.
-
Media article: ICON teams with Advarra for integrated, AI-driven site network
ICON and Advarra partnership creates an integrated site-centric system that tackles operational bottlenecks and simplifies study execution, addressing sponsors most pressing challenges.
-
Media article: ICON, Advarra partnership aims to optimize trials, expand access
ICON and Advarra have partnered to create a connected network of clinical trial sites that integrates ICON’s global trial solutions with Advarra’s site technologies, aiming to streamline study operations, boost efficiency, and expand trial access.
-
Media article: ICON partners with Advarra to launch connected site network model
ICON and Advarra have formed a partnership to create a connected, research ready site network that integrates ICON’s clinical trial services with Advarra’s site-facing technology to streamline study startup and trial execution. The collaboration aims to reduce administrative burden, enhance operational visibility, and broaden trial access by standardising workflows for both established and emerging research sites.
-
Media article: ICON, Advarra partner on connected site network model
ICON plc and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
-
Media article: Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
-
Media article: US Pharma and Biotech Summit 2024: Evolving clinical research
In this news article, Applied Clinical Trials reports on ICON CEO Steve Cutler’s discussion at the FT US Pharma and Biotech Summit.
-
Media article: Toward more intelligent collaboration: implementing data in partnerships
This article outlines how data can play a key role in supporting collaboration and achieving objectives, as strategic partnerships become more important in clinical resea
